$(0.31)$(0.38)$(0.91)$(1.51)Shares used in calculating net loss per share, basic & diluted
117,40990,995105,58281,518Arena Pharmaceuticals, Inc.Condensed Consolidated Balance Sheet Data(In thousands)September 30, 2010December 31, 2009(unaudited)*Assets Cash, cash equivalents & short-term investments
$ 176,536$ 115,449 Accounts receivable
1,9721,415 Other current assets
3,2744,409 Land, property & equipment, net
93,08195,445 Acquired technology & other non-current assets
$ 293,040$ 236,278Liabilities and Stockholders' Equity Accounts payable and accrued liabilities
$ 13,762$ 15,884 Total deferred revenues
49,0464,086 Total derivative liabilities
1,7856,642 Total note payable to Siegfried
9,8889,143 Total note payable to Deerfield**35,43447,906 Total lease financing obligations & other long-term liabilities
77,41978,050 Total stockholders' equity
105,70674,567Total liabilities & stockholders' equity
$ 293,040$ 236,278* The condensed consolidated balance sheet data as of December 31, 2009, has been derived from the audited financial statements as of that date.
** The outstanding principal balance of the note payable to Deerfield was $60.0 million and $90.0 million at September 30, 2010 and December 31, 2009, respectively.
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved